Ethicon Expands Advanced Biopolar Energy Portfolio With Launch Of Enseal X1 Curved Jaw Tissue Sealer

CINCINNATI, OH – June 21, 2021 -- Ethicon*, part of the Johnson &Johnson Medical Devices Companies,** today announced the launch of the ENSEAL X1 Curved Jaw Tissue Sealer, a new advanced bipolar energy device that increases procedural efficiency[1] and provided stronger sealing[2] and better access to more tissue than LigaSure™ Maryland.[3] The device is indicated for colorectal, gynecological, bariatric surgery and thoracic procedures. The ENSEAL X1 Curved Jaw is the first of several new advanced laparoscopic bipolar devices the company plans to launch in the coming months as it expands its extensive energy portfolio, which includes market-leading HARMONIC ultrasonic devices and MEGADYNE core electrosurgical tools. Among the ENSEAL X1 Curved Jaw’s new features are separate seal and cut capabilities, a 360-degree continuous shaft rotation that enables easy access to targeted tissue,[4] and Ethicon’s Adaptive Tissue Technology, which enables the device to continuously sense changes in the condition of tissue and respond accordingly with the optimal amount of energy to minimize lateral thermal spread.[5],[6] These features, including improved ergonomics and a one-handed operation, combine to offer precision, a secure seal and a more intuitive and simplified use that may deliver greater efficiency in the operating room.[7],[8],[9],[10] “This is an intelligent and intuitive energy device that provides secure sealing and an ease of use that improv...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

During her career, Debbie DiCarlo had worked for nonprofits dealing with immigration, foster case, sex trafficking and domestic violence, but she never saw herself working for a cancer organization. That is, until her best friend was diagnosed with cancer, and she subsequently moved to the Valley from California to do just that.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
A new analysis of data from the THALES trial separates out the reduction in ischemic events from the increase in bleeding events and shows the benefit outweighs the risk in a ratio of four-to-one.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news
During her career, Debbie DiCarlo had worked for nonprofits dealing with immigration, foster case, sex trafficking and domestic violence, but she never saw herself working for a cancer organization. That is, until her best friend was diagnosed with cancer, and she subsequently moved to the Valley from California to do just that.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
Shares of a Bay Area biotech company shot up more than 157% and another climbed to a lesser degree Friday after a Big Pharma company reported that a cancer drug with a shared target appeared effective in fighting tumors. Both Corvus Pharmaceuticals Inc. (Nasdaq: CRVS) of Burlingame and Arcus Biosciences Inc. (NYSE: RCUS) of Hayward shot up after AstraZeneca plc reported fresh data from a mid-stage clinical trial. That Big Pharma player said its already-approved cancer immunotherapy Imfinzi showed…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Koios Medical recently entered into a strategic partnership with GE Healthcar...Read more on AuntMinnie.comRelated Reading: AI can help classify masses found on breast ultrasound Koios secures FDA breakthrough designation for breast AI Koios Medical's AI for detecting breast cancer gets CE Mark Koios touts study on AI for breast biopsy FDA clears Koios Medical's breast cancer software
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
BLOOD clots can be "dangerous", the American Society of Haematology warned. Usually, coagulation is an important process to prevent excessive bleeding when a blood vessel is injured.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
This study aims to explore the effect of the ITI (interferon alpha-1b, thalidomide, and interleukin-2) regimen on the AML1-ETO fusion gene in patients with t(8;21) acute myeloid leukemia (AML) who were in hematologic remission but positive for the AML1-ETO fusion gene. From September 2014 to November 2020; 20 patients with AML (15 from The Affiliated Cancer Hospital of Zhengzhou University, 4 from The First Affiliated Hospital; and College of Clinical Medicine of Henan University of Science and Technology, and 1 from Anyang District Hospital) with hematological remission but AML1-ETO fusion gene positivity were treated wit...
Source: Annals of Hematology - Category: Hematology Source Type: research
AbstractWe investigated the feasibility and activity of an intensified dose-dense ABVD (dd-ABVD) regimen in patients with early-stage unfavorable Hodgkin lymphoma (HL). This prospective, multicenter, phase II study enrolled 96 patients with newly diagnosed, unfavorable stage I or II classical HL. The patients received four cycles of dd-ABVD followed by radiotherapy. Interim PET (PET-2) was mandatory after two courses. Primary endpoints were the evaluation of dd-ABVD feasibility and activity (incidence of PET-2 negativity). The feasibility endpoint was achieved with 48/52 (92.3%) patients receiving  >  85% ...
Source: Annals of Hematology - Category: Hematology Source Type: research
AbstractAcute myeloid leukemia (AML) relapse after allogeneic stem cell transplant (alloSCT) remains a major therapeutic challenge. While patients with longer remission after initial alloSCT are recommended to receive cell therapy (CT) such as 2ndalloSCT or donor lymphocyte infusion (DLI), survival for patients who relapse within 6  months of alloSCT has been dismal. We evaluated the outcomes of AML relapse after alloSCT to assess the impact of different treatments on long-term survival. One hundred and seventy-two patients with AML underwent alloSCT at the Penn State Cancer Institute from January 2014 to August 2019....
Source: Annals of Hematology - Category: Hematology Source Type: research
Children aged 6 to 11 had the most significant increases in rates of obesity, the AP reported.
Source: WebMD Health - Category: Consumer Health News Source Type: news
More News: Bariatric Surgery | Bipolar | Bleeding | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Colorectal Cancer | Eating Disorders & Weight Management | Health Management | Laparoscopy | Legislation | Mania | Medical Devices | Medical Ethics | Obesity | Orthopaedics | Pharmaceuticals | Science | Warnings